Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 5/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.56 |
| ▸ | RET | P07949 | 3/20 | 0.55 |
| ▸ | RAF1 | P04049 | 9/20 | 0.55 |
| ▸ | KDR | P35968 | 6/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15141391 | 0.94 | BRAF (0.56) | BRAFMAPK14RETRAF1KDR | |
| SCHEMBL16507111 | 0.93 | RAF1 (0.54) | BRAFMAPK14RETRAF1KDR | |
| SCHEMBL15141394 | 0.93 | KDR (0.54) | BRAFMAPK14RETRAF1KDR | |
| SCHEMBL16507244 | 0.93 | RET (0.46) | BRAFMAPK14RETRAF1KDR | |
| SCHEMBL15148006 | 0.92 | RET (0.47) | BRAFMAPK14RETRAF1KDR | |
| SCHEMBL16506752 | 0.92 | BRAF (0.62) | BRAFMAPK14RETRAF1KDR | |
| SCHEMBL16507325 | 0.91 | BRAF (0.52) | BRAFMAPK14RETRAF1KDR | |
| SCHEMBL15147778 | 0.91 | RAF1 (0.56) | BRAFMAPK14RETRAF1KDR | |
| SCHEMBL15148079 | 0.91 | RAF1 (0.56) | BRAFMAPK14RETRAF1KDR | |
| SCHEMBL15140869 | 0.90 | RAF1 (0.58) | BRAFMAPK14RETRAF1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2806874-B1 | Quinoxaline-oxy-phenyl derivatives as kinase inhibitors | NEUPHARMA INC (US) | 2017-11-15 | — | — | EP | claimed |
| US-9670180-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2017-06-06 | — | — | US | claimed |
| US-20150057277-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-02-26 | — | — | US | claimed |
| US-10590106-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-9908866-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| EP-2806874-B1 | Quinoxaline-oxy-phenyl derivatives as kinase inhibitors | NEUPHARMA INC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170283395-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9670180-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20150057277-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590106-B2 | Certain chemical entities, compositions, and methods | PDXK, DCK, CHEK1 | BRAF 15/4885MAPK14 950/4885RET 448/4885 |
| US-20150057277-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | PDXK, DCK, CHEK1 | BRAF 15/4885MAPK14 950/4885RET 448/4885 |
| US-20170283395-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | PDXK, DCK, CHEK1 | BRAF 15/4885MAPK14 950/4885RET 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.